Research Use Only. The information presented here is for scientific and educational purposes. These compounds are not intended for human consumption, self-administration, or therapeutic use.
Introduction
FOXO4-DRI is a synthetic peptide that has become a widely cited research tool in the study of cellular senescence, the state in which cells stop dividing yet remain metabolically active. Its name reflects its design: it is a D-retro-inverso (DRI) isoform built around a short segment of the FOXO4 protein, engineered to interfere with the physical interaction between FOXO4 and the tumor suppressor protein p53. In laboratory models, this protein-protein interaction is one of the mechanisms thought to allow senescent cells to persist rather than undergo programmed cell death.
Interest in FOXO4-DRI sits within a broader field known as senolytics, the study of compounds that selectively remove senescent cells in experimental systems. Every observation discussed below comes from in-vitro assays and animal-model research, and none of it describes human use. FOXO4-DRI is described here strictly for research use only, not for human consumption, and this overview summarizes published preclinical findings rather than any clinical outcome.
What Is FOXO4-DRI?
A designed D-retro-inverso peptide
The DRI designation is central to how FOXO4-DRI is constructed. A retro-inverso peptide reverses the order of the amino acid sequence and substitutes D-amino acids for the naturally occurring L-amino acids. The result is a molecule that presents a similar arrangement of side chains to its target while resisting the proteases that would rapidly degrade an ordinary peptide. For researchers, this design is attractive because it improves stability in cell-culture and animal-model experiments. The functional construct also incorporates a cell-penetrating segment intended to help the peptide cross membranes in these systems.
The FOXO4 transcription factor context
FOXO4 belongs to the forkhead box O (FOXO) family of transcription factors, proteins that regulate genes involved in stress responses, metabolism, and cell-cycle control. In senescent cells, FOXO4 is reported to be elevated and to associate with p53. By binding p53 and holding it in the cell nucleus, FOXO4 is thought to keep senescent cells from triggering apoptosis, the orderly self-destruction pathway. FOXO4-DRI was designed specifically to compete with this interaction.
The attributes below reflect commonly reported laboratory attributes and are provided for comparison only.
| Attribute | Reported detail |
|---|---|
| Compound name | FOXO4-DRI (FOXO4 D-retro-inverso peptide) |
| Class | Synthetic peptide (D-retro-inverso isoform) |
| Design feature | Reversed sequence with D-amino acids for protease resistance |
| Peptide size | Mid-sized synthetic construct including a cell-penetrating segment (exact mass varies by preparation) |
| Molecular target | FOXO4-p53 protein-protein interaction |
| Mechanism studied | Disruption of FOXO4-p53 binding (senolytic research) |
| Model systems | In-vitro senescent cell cultures and rodent models |
| Status | Research use only, not for human consumption |
The p53-FOXO4 Axis in Cellular Senescence
Why senescent cells resist clearance
Senescent cells accumulate in tissues with age and after certain stresses, such as DNA damage. Although they no longer divide, they remain in place and secrete a mix of signaling molecules known collectively as the senescence-associated secretory phenotype (SASP). A recurring question in senescence research is why these cells are unusually resistant to apoptosis. One proposed answer involves FOXO4: by sequestering p53 in the nucleus, FOXO4 is thought to prevent p53 from relocating to the mitochondria, where it would otherwise help initiate the apoptotic cascade.
What the peptide does in models
FOXO4-DRI is used experimentally to test this hypothesis. In cell and animal studies, introducing the peptide is reported to release p53 from FOXO4, allowing a portion of p53 to move to the mitochondria and drive apoptosis preferentially in senescent cells. Because proliferating cells are described as not depending on the same FOXO4-p53 arrangement, the effect is reported as relatively selective for senescent cells in these systems. This selective clearance, or senolysis, is the core research readout associated with the compound.
The values below reflect commonly reported laboratory attributes and are provided for comparison only.
| Research strategy | Molecular class | Reported mechanism in models |
|---|---|---|
| FOXO4-DRI | Peptide (D-retro-inverso) | Disrupts FOXO4-p53 interaction to release p53 |
| BCL-2 family inhibitors | Small molecule | Interfere with anti-apoptotic BCL-2 proteins |
| Kinase plus flavonoid combinations | Small molecules | Target survival pathways in senescent cells |
| Flavonoid compounds | Small molecule | Investigated for senescent-cell clearance |
FOXO4-DRI in Preclinical Research Models
In-vitro senescence assays
Much of the foundational work uses cultured cells pushed into senescence by irradiation, chemotherapy-style agents, or replicative exhaustion. In these assays, researchers measure markers such as senescence-associated beta-galactosidase activity and cell viability after peptide exposure. Reports describe reduced numbers of marker-positive cells, consistent with selective senolysis, while dividing control cells appear less affected. These are controlled laboratory readouts, not indications of any effect in living people.
Rodent-model observations
The most cited animal work comes from research groups studying aging biology, including the 2017 study led by Peter de Keizer and colleagues. Using naturally aged mice, fast-aging (progeroid) mouse strains, and mice exposed to the chemotherapy agent doxorubicin, investigators reported changes in markers of tissue function after repeated peptide dosing. These rodent observations, including reported effects on coat condition, activity levels, and kidney markers, are strictly animal-model findings. They do not establish safety or effect in humans, and no human anti-aging or longevity claim can be drawn from them.
Interpreting the evidence
As with any research tool, the peptide’s reported effects depend heavily on the model, dose, and timing. Independent replication and mechanistic follow-up remain active areas of study. Published results are best treated as preclinical signals that guide further laboratory work, not as demonstrations of clinical benefit.
Sourcing, Purity, and Related Research Compounds
Why documentation matters
For any peptide used in a laboratory setting, identity and purity determine whether results are interpretable. Reviewing a certificate of analysis and third-party testing is a basic step before an experiment. Our guide on how to read a peptide COA explains the purity, mass-spectrometry, and identity fields worth checking, and our overview of how to choose a research peptide supplier outlines how to vet vendors. Published certificates of analysis provide an additional reference point.
Related compounds in longevity and mitochondrial research
FOXO4-DRI is one entry point into a wider set of compounds examined in longevity and mitochondrial biology. Researchers working in adjacent areas also study NAD+ as a metabolic cofactor, MOTS-c as a mitochondrial-derived peptide, and SS-31 for its association with mitochondrial membranes. These are distinct molecules with their own mechanisms, mentioned here only to place FOXO4-DRI within the broader research landscape, not to imply equivalence. Each, like FOXO4-DRI, is intended for research use only, not for human consumption.
Frequently Asked Questions
What is FOXO4-DRI?
FOXO4-DRI is a synthetic D-retro-inverso peptide designed to disrupt the interaction between the FOXO4 protein and the tumor suppressor p53. It is used as a research tool in the study of cellular senescence and senolytics. It is intended for research use only and is not for human consumption.
How does FOXO4-DRI work in senescence research?
In laboratory models, FOXO4-DRI competes with p53 for binding to FOXO4. Releasing p53 is reported to allow a portion of it to reach the mitochondria and trigger apoptosis, which appears relatively selective for senescent cells in these systems. This selective clearance is called senolysis.
Is FOXO4-DRI a senolytic?
In the research literature, FOXO4-DRI is classified as a peptide-based senolytic, meaning it is studied for its ability to remove senescent cells in experimental models. This classification comes from in-vitro and animal studies, not from human data.
How is FOXO4-DRI different from small-molecule senolytics?
FOXO4-DRI is a peptide that targets a specific protein-protein interaction (FOXO4-p53), whereas many other senolytics studied in the laboratory are small molecules that act on anti-apoptotic or survival pathways. The peptide’s retro-inverso design is intended to improve its stability in experimental systems.
Has FOXO4-DRI been studied in humans?
Published FOXO4-DRI research is preclinical. It comes from cell-culture experiments and rodent models, including aged and progeroid mice. No human anti-aging or longevity claims can be made, and the peptide is not intended for human use.
What should researchers check before sourcing FOXO4-DRI?
Because peptide identity and purity affect results, researchers typically review a certificate of analysis, mass-spectrometry identity, and third-party testing before use. Our COA guide and supplier vetting resource describe what to verify. All such material is for research use only.
References and Further Reading
- Baar and colleagues (2017), foundational report on targeted apoptosis of senescent cells: PubMed: FOXO4-DRI senescence
- FOXO4 and p53 interaction in senescent cells: PubMed: FOXO4 p53 senescent cells
- Overview of senolytics and aging biology: PubMed: senolytics aging
- Apoptosis resistance in senescent cells: PubMed: cellular senescence apoptosis resistance
- Retro-inverso and D-amino acid peptide design: PubMed: retro-inverso peptide design
- p53 mitochondrial apoptosis pathway: PubMed: p53 mitochondrial apoptosis
- Doxorubicin-induced senescence models: PubMed: doxorubicin induced senescence
